Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome
Open Access
- 1 November 2013
- journal article
- Published by Elsevier in Kidney International
- Vol. 84 (5) , 1025-1033
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Rituximab in Children with Resistant Idiopathic Nephrotic SyndromeJournal of the American Society of Nephrology, 2012
- Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2011
- Rituximab Targets Podocytes in Recurrent Focal Segmental GlomerulosclerosisScience Translational Medicine, 2011
- Rituximab resistanceBest Practice & Research Clinical Haematology, 2011
- Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2010
- Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in ChildrenClinical Journal of the American Society of Nephrology, 2009
- Fatal pulmonary fibrosis after rituximab administrationPediatric Nephrology, 2009
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 casesPediatric Nephrology, 2008
- Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursorBlood, 2006
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005